NetworkNewsBreaks – Vivos Therapeutics Inc. (NAS
Post# of 51
(Total Views: 320)
Posted On: 03/08/2021 3:24:03 PM
NetworkNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Opens First-Ever Pneusomnia Clinic, Unveils New Tech to Test for Sleep Apnea at Home
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”), has opened the first Pneusomnia clinic, a clinician-owned, integrated medical-dental sleep center. The center will feature the Vivos System through its Medical Integration Division. Located in Del Mar, California, the clinic is owned and operated by local physicians, including Dr. Mimi Guarneri, a cardiologist, founder and president of the Academy of Integrative Health and Medicine; she will lead the center. Vivos created its Medical Integration Division last year with the objective of fostering an environment where medical doctors and dentists could work together in treating sleep disorders. The new sleep medicine center will offer the Vivos System, a clinically effective, nonsurgical, noninvasive, nonpharmaceutical oral appliance treatment for mild-to-moderate sleep apnea. In addition to the opening of the new center, Vivos recently launched a new testing technology called VivoScore(TM), powered by SleepImage(R). According to the announcement, VivoScore is a home sleep apnea test (“HSAT”) that builds upon proprietary cardiopulmonary coupling technology developed by SleepImage, or MyCardio LLC, which has been FDA cleared for the purpose of diagnosing OSA. The device includes a single-sensor ring recorder that connects with a smartphone app and uses proprietary cloud-based algorithms to evaluate sleep quality and clinically diagnose sleep apnea in a person’s own home. Studies indicate that VivoScore test results are comparable to overnight in-lab polysomnogram (“PSG”) tests. VivoScore can be used for both children and adults, and is designed to increase access and decrease costs of other HSAT options. “With the medical and dental communities coming together through the Pneusomnia clinics to both diagnose and treat OSA, patients will have access to the Vivos System, our leading-edge technology that helps to alter the size, shape and position of their upper airway tissues,” said Vivos CEO Kirk Huntsman in one of the press releases. “We look forward to continuing our work with Dr. Guarneri to bring as many patients into the new facility as possible. With additional centers opening later this year across the country, and over 1,200 independent dentists in the U.S. and Canada who are now using the Vivos System, we believe we are poised to reach even more undiagnosed patients than ever before.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”), has opened the first Pneusomnia clinic, a clinician-owned, integrated medical-dental sleep center. The center will feature the Vivos System through its Medical Integration Division. Located in Del Mar, California, the clinic is owned and operated by local physicians, including Dr. Mimi Guarneri, a cardiologist, founder and president of the Academy of Integrative Health and Medicine; she will lead the center. Vivos created its Medical Integration Division last year with the objective of fostering an environment where medical doctors and dentists could work together in treating sleep disorders. The new sleep medicine center will offer the Vivos System, a clinically effective, nonsurgical, noninvasive, nonpharmaceutical oral appliance treatment for mild-to-moderate sleep apnea. In addition to the opening of the new center, Vivos recently launched a new testing technology called VivoScore(TM), powered by SleepImage(R). According to the announcement, VivoScore is a home sleep apnea test (“HSAT”) that builds upon proprietary cardiopulmonary coupling technology developed by SleepImage, or MyCardio LLC, which has been FDA cleared for the purpose of diagnosing OSA. The device includes a single-sensor ring recorder that connects with a smartphone app and uses proprietary cloud-based algorithms to evaluate sleep quality and clinically diagnose sleep apnea in a person’s own home. Studies indicate that VivoScore test results are comparable to overnight in-lab polysomnogram (“PSG”) tests. VivoScore can be used for both children and adults, and is designed to increase access and decrease costs of other HSAT options. “With the medical and dental communities coming together through the Pneusomnia clinics to both diagnose and treat OSA, patients will have access to the Vivos System, our leading-edge technology that helps to alter the size, shape and position of their upper airway tissues,” said Vivos CEO Kirk Huntsman in one of the press releases. “We look forward to continuing our work with Dr. Guarneri to bring as many patients into the new facility as possible. With additional centers opening later this year across the country, and over 1,200 independent dentists in the U.S. and Canada who are now using the Vivos System, we believe we are poised to reach even more undiagnosed patients than ever before.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Vivos Therapeutics Inc. (VVOS) Stock Research Links
Scroll down for more posts ▼